Patent US4515893A successfully refreshed from Google Patents.
US4515893A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
Assignee: Ortho Pharmaceutical Corp
•
Filing: 1982-10-04
•
Granted: 1985-05-07
•
Expires: 2002-10-04
Abstract
Abstract Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells and cutaneous T lymphoma cells. The hybrid is formed by fusing splenocytes from immunized CAF1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Inventors
- 👤 Patrick C. Kung
- 👤 Gideon Goldstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:29
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/57505; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; C07K16/2809; G01N33/569; G01N33/56966; G01N33/56972; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
151 words
An IgG monoclonal-antibody-producing hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human T cells, which antibody: (a) reacts with essentially all normal human peripheral T cells and cutaneous T lymphoma cells, but not with normal human peripheral B cells, null cells or macrophages; (b) reacts with from about 5% to about 10% of normal human thymocytes; (c) reacts with leukemic cells from humans with T cell chronic lymphoblastic leukemia but does not react with leukemic cells from humans with T cell acute lymphoblastic leukemia, null cell acute lymphoblastic leukemia, or B cell chronic lymphatic leukemia; (d) reacts weakly with the human T cell line HJD-1 but does not react with CEM, Laz 191, or HMl; (e) does not react with the Epstein-Barr virus-transformed human B cell lines Laz 007, Laz 156, Laz 256, or SB; and (f) fixes complement.
Claim 2
Dependent Claim
151 words
An IgG monoclonal-antibody-producing hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human T cells, which antibody: (a) reacts with essentially all normal human peripheral T cells and cutaneous T lymphoma cells, but not with normal human peripheral B cells, null cells or macrophages; (b) reacts with from about 5% to about 10% of normal human thymocytes; (c) reacts with leukemic cells from humans with T cell chronic lymphoblastic leukemia but does not react with leukemic cells from humans with T cell acute lymphoblastic leukemia, null cell acute lymphoblastic leukemia, or B cell chronic lymphatic leukemia; (d) reacts weakly with the human T cell line HJD-1 but does not react with CEM, Laz 191, or HMl; (e) does not react with the Epstein-Barr virus-transformed human B cell lines Laz 007, Laz 156, Laz 256, or SB; and (f) fixes complement.
Claim 3
Dependent Claim
16 words
The hybridoma of claim 1 wherein the antibody produced thereby is of subclass IgG 2 .
Claim 4
Dependent Claim
31 words
The hybridoma of claim 1 which is formed by fusion of P3X63Ag8U1 myeloma cells and spleen cells from a CAF 1 mouse previously immunized with E rosette purified human T cells.
Claim 5
Dependent Claim
14 words
A hybridoma according to claim 1 having the identifying characteristics of ATCC CRL 8001.
Claim 6
Dependent Claim
31 words
A hybridoma capable of producing mouse complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages.
Claim 7
Dependent Claim
31 words
A hybridoma capable of producing mouse complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages.
Claim 8
Dependent Claim
56 words
A hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human T cells, which hybridoma is capable of producing a complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages.
Claim 9
Dependent Claim
56 words
A hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human T cells, which hybridoma is capable of producing a complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages.
Claim 10
Dependent Claim
19 words
A hybridoma capable of producing complement-fixing mouse monoclonal antibody that reacts with essentially all normal human peripheral T cells.
Claim 11
Dependent Claim
19 words
A hybridoma capable of producing complement-fixing mouse monoclonal antibody that reacts with essentially all normal human peripheral T cells.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-05-06 | 1988-11-05 | 1989-05-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-05-06 | 1992-11-05 | 1993-05-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-05-06 | 1996-11-05 | 1997-05-07 | $7700.00 | Window Closed / Lapsed |